Shares of Mirati Therapeutics (NASDAQ: MRTX), a clinical-stage biotechnology company developing new cancer drugs, are on the move thanks to enthusiasm for its experimental KRAS inhibitor.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,